BioLineRx Ltd.
BLRX
$4.64
$0.06781.48%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
6/6/2025
-
MarketBeat
5/31/2025
-
Insider Monkey
5/31/2025
-
Yahoo! Finance: News
5/31/2025
-
Insider Monkey
5/31/2025
-
Ticker Report
5/30/2025
-
Stocktwits News Feed
5/30/2025
-
GuruFocus
5/30/2025
-
The Fly
5/30/2025
-
GuruFocus
5/30/2025
-
TipRanks Financial Blog
5/30/2025
-
GuruFocus
5/30/2025
-
GuruFocus
5/30/2025
-
The Fly
5/30/2025
-
PR Newswire
5/28/2025
-
Ticker Report
5/28/2025
-
Insider Monkey
BioLineRx projects cash runway into H2 2026 while advancing PDAC pipeline and APHEXDA royalty growth
5/28/2025
-
Seeking Alpha - Israel Stocks
5/28/2025
-
TipRanks Financial Blog
5/27/2025
-
Stocktwits News Feed
5/27/2025
-
SeekingAlpha
5/27/2025
-
Seeking Alpha - Israel Stocks
5/27/2025
-
Seeking Alpha: Transcripts
5/27/2025
-
GuruFocus
5/27/2025
-
GuruFocus
5/27/2025
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, May 27, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
972 8 642 9100
Address
Modi’in Technology Park
Hevel Modi'in, 7177871
Hevel Modi'in, 7177871
Country
Year Founded
Business Description
Sector
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a...
more